Tiziana Life Sciences has pointed to increased Big Pharma interest in the IL-6 pathway as justification for its ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that it intends to develop its ...

The IL-6 receptor antagonist market presents significant opportunities in underexplored areas like thyroid eye disease and atherosclerotic cardiovascular disease (ASCVD). Recent acquisitions and ...

Tiziana Life Sciences considers the antibody, known as TZLS-501, to have potential to operate as a standalone business and intends to proceed with steps for a publicly-listed immunology-focused ...

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday it plans to spin out its anti-IL-6 receptor antibody program, TZLS-501, into a separately ...

New study examines the oral pathogen Porphyromonas gingivalis ( Pg ) and suggests its influence may extend beyond dental ...

Soficitinib is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders. The Current indications under development are ...

Mito-TEMPO（AbMole，M10919）的作用机制不仅限于简单的ROS清除，它还能调节多种线粒体相关信号通路和细胞生命活动。例如Mito-TEMPO在MCF-7细胞中，逆转了DHA诱导的ROS依赖性自噬激活，通过调节p-AMPKα/p-Ra ...

Evaluation in 18 patients with polycythemia vera showed hematocrit control below 45%, accompanied by a "dramatic decrease in ...

Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced initial clinical results from 1st two cohorts of its ongoing Phase 1 ...

Our body experiences heart disease, diabetes, joint pain and brain decline because of ongoing low-level inflammation. Certain ...